



JFL LIFE SCIENCES LIMITED

Date: August 11, 2025

To,
The Manager,
Listing Department
The National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Dear Sir/Madam,

NSE Symbol: JFLIFE; ISIN: INE0LA901015

Subject: Outcome of Board Meeting held on Monday, August 11, 2025

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that a meeting of the Board of Directors of JFL Life Sciences Limited ("the Company") has been held on August 11, 2025, at 02:00 P.M. which concluded at 03:30 PM and Board has approved the following:

1. Unaudited financial results for year ended June 30, 2025 along with Limited Review Report.
2. Appointment of Ms. Khyati Shah as additional Independent Director of the Company.

Detailed information as required under Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, in respect of aforesaid Appointment is given in '**Annexure A**' to this letter.

3. Approved increase in Managerial Remuneration to Rs. 24,00,000/- p.a. of Mr. Smiral Ashwinkumar Patel, Managing Director of the Company, subject to approval of shareholders of the company in the ensuing general meeting.

Thanking You

Yours Truly,

For JFL LIFE SCIENCES LIMITED

SMIRAL ASHWINKUMAR PATEL

Managing director
DIN: 00769486

Encl: A/a

Registered Office Address : 309, Satyam Mall, Opp. Saman Complex, Nr.Vishweshwar Mahadev Mandir, Satellite, Ahmedabad-380015.

Unit-I : 615, G.I.D.C. Estate Kerala, Bavla, Ahmedabad, Gujarat-382220.

Unit-II : 406,407, G.I.D.C. Kerala, Bavla, Ahmedabad, Gujarat-382220.

CIN : L24230GJ2010PLC060417 | **Contact No.:** 9377295575 | **Email :** info@jfllifesciences.com | **Website :** www.jfllifesciences.com

Annexure A

Details as required under SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123
dated July 13, 2023

SRN	PARTICULARS	INFORMATION OF SUCH EVENT
1	Name of appointee and designation	Ms. Khyati Bhavya Shah (DIN: 09430457) Additional Director (Non-executive Independent director)
2	reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Appointment
3	Date of appointment/ re-appointment/cessation (as applicable) & term of appointment/ re-appointment;	11-08-2025, subject to approval of shareholders in the ensuing general meeting Terms of Appointment: For the period of five years from the date of appointment subject to shareholders approval.
4	Brief profile	Ms. Khyati Bhavya Shah is an accomplished corporate professional with extensive experience in governance, compliance, and strategic advisory roles. She has served as an Independent Director on the boards of listed entities, contributing to policy formulation, risk oversight, and ethical business practices. Her expertise spans financial management, regulatory compliance, and strategic planning across diverse industries.
5	Disclosure of relationships between directors (in case of appointment of a director)	Ms. Shah is not related to any of the Directors or Key Managerial Personnel or Promoters and Promoter group of the Company
6	Information as required under BSE circular no. LIST/COMP/14/2018-19, dated June 20, 2018.	Ms. Shah is not debarred from holding the office of Director by any SEBI order or any other such authority.

JFL Life Sciences Limited

CIN : L24230GJ2010PLC060417

Reg Office :- 309, SATYAM MALL, OPP. SAMAN COMPLEX, NR. VISHWESHWAR MAHADEV MANDIR, SETTELITE, AHMEDABAD 380015

Tele No. +91-93772 95575, Email id :- info@jfllifesciences.com, www.jfllifesciences.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2025

Sr. No.	PARTICULARS.	Quarter Ended on	Quarter Ended on	Quarter Ended on	Year Ended on
		30.06.2025	31.03.2025	30.06.2024	31.03.2025 (Audited)
	INCOMES				
I	Revenue from Operations	1,158.54	1,173.21	954.49	8,204.23
II	Other Income	0.28	0.13	0.40	1.01
III	Total Income (I + II)	1,158.82	1,173.34	954.89	8,205.24
IV	EXPENSES.				
(a)	Cost of materials consumed	759.23	752.03	644.99	6,677.44
(b)	Changes of Inventories of Finished Goods, -Work in Progress, Stock in Trade.	8.10	6.07	(100.98)	(66.30)
(c)	Employee benefits expense	23.21	26.75	59.42	101.09
(d)	Finance Cost	24.48	33.17	26.30	108.12
(e)	Depreciation and Amortisation Expenses	26.40	35.51	23.91	99.25
(f)	Other Expenses	174.65	250.81	45.42	672.10
	TOTAL EXPENSES (IV (a to f))	1,016.06	1,104.34	699.06	7,591.70
V	Profit/(Loss) before Exceptional Items and Tax. (III-IV)	142.76	69.00	255.82	613.54
VI	Exceptional Items. & Extraordinary Item	-	-	-	-
VII	Profit/ (Loss) Before Tax. (V-VI)	142.76	69.00	255.82	613.54
VIII	TAX EXPENSES.				
(a)	Current Tax.	22.59	19.37	62.71	152.78
(b)	Deferred Tax.	45.54	41.25	1.69	44.90
	Total Tax Expenses.	68.13	60.63	64.40	197.69
IX	NET PROFIT / (LOSS) FOR THE PERIOD	74.63	8.38	191.42	415.86
X	Items that will not be reclassified to profit or loss				
(i)	Re-measurement gains on defined benefit plans	0.09	0.36	-	0.36
	Other comprehensive income for the year, net of tax	74.54	8.02	191.42	415.50
	Total comprehensive income for the year	74.54	8.02	191.42	415.50
XI	Paid up Equity Share Capital (Amount in lacs)	329.95	329.95	109.98	329.95
	Rs. 10 Face value per share)	Rs. 10/-	Rs. 10/-	Rs. 10/-	Rs. 10/-
XII	Earning Per Share (In Rupees) from				
(i)	Basic.	0.23	0.03	1.74	1.26
(ii)	Diluted.	0.23	0.03	1.74	1.26

NOTES:

- These financial result were reviewed by the Board of Directors and Audit Committee thereafter have been approved by the board of directors at its meeting held on Monday, August 11th, 2025. The Statutory Auditors have carried out Review of the Unaudited Financial Result for the Quarter ended on 30th June, 2025.
- Financial results for the periods presented have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (as amended from time to time) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended.
- Company has only one reportable segment - Pharmaceuticals Manufacturing.
- Figures for the previous period have been regrouped/ rearranged/ reclassified wherever considered necessary to correspond with the current period's classification/group's disclosure.

For JFL Life Sciences Limited

Smiral A. Patel
Managing Director
DIN : 00769486
Date: August 11, 2025
Place : Ahmedabad



Independent Auditor's Review Report on the Quarter Ended June 30, 2025, Unaudited Financial Results of JFL LIFE SCIENCES LIMITED pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To

The Board of Directors

JFL LIFE SCIENCES LIMITED

309, Satyam Mall, Opp. Saman Complex,
Nr. Vishweshwar Mahadev Mandir, Settelite,
Ahmedabad, Gujrat, India, 380015

1. We have reviewed the accompanying statement of unaudited financial results of **JFL Life Sciences Limited** (the 'Company') for the quarter ended June 30, 2025 (the "Statement"). This statement is prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.


A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results, prepared in accordance with applicable Indian Accounting Standards and other recognized accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulation of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Doshi Doshi & Co,**
Chartered Accountants
Firm Registration No.: 153683W



Chintan R. Doshi
Partner
Membership No.: 158931
UDIN: 25158931BMIGHU2972



Place: Ahmedabad
Date: August 11, 2025

9167 404 303
chintan@ddco.in
www.ddco.in

📍 **Ahmedabad Branch**
C 908, Stratum @ Venus Ground,
NR Jhansi Ki Rani Statue,
Nehrunagar Ahmedabad - 380015

📍 **Mumbai Branch**
119, Plot No. 7, Near F M Banquets,
Udyog Nagar, Goregaon West,
Mumbai - 400104